NHS England will offer wearable drug pumps to up to 1,000 advanced Parkinson's patients, replacing the need to take up to 20 tablets a day. The portable infusion devices deliver foslevodopa-foscarbidopa directly into the bloodstream, enhancing movement control and reducing side effects. Eligible patients include those with severe motor fluctuations and who are not responding to oral treatments, with rollout expected in the coming weeks. Clinical trials have shown the treatment to be safe and effective, with patients reporting significant improvements in symptom management and quality of life. Parkinson's UK hails the introduction of the wearable pumps as a life-changing option, though it may not be suitable for all patients.